SCHEDULE 13D/A
SCHEDULE 13D/ASchedule 13D ownership disclosure
LANTERN PHARMA INC
Common Stock, par value $0.0001 per share · CUSIP: 51654W101
Event date: 2025-06-12
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- BIOS FUND I, LPReported CIK 0001697316
Shares: 323,335.00 · Class: 3.00%
- BIOS FUND I QP, LPReported CIK 0001700297
Shares: 189,117.00 · Class: 1.75%
- BIOS FUND II, LPReported CIK 0001714576
Shares: 114,272.00 · Class: 1.06%
- BIOS FUND II QP, LPReported CIK 0001716869
Shares: 373,178.00 · Class: 3.46%
- BIOS FUND II NT, LPReported CIK 0001728851
Shares: 49,957.00 · Class: 0.46%
- BP DIRECTORS, LPReported CIK 0001813311
Shares: 26,093.00 · Class: 0.24%
- BIOS EQUITY PARTNERS, LPReported CIK 0001813314
Shares: 538,545.00 · Class: 4.99%
- BIOS EQUITY PARTNERS II, LPReported CIK 0001813313
Shares: 537,407.00 · Class: 4.98%
- CAVU MANAGEMENT, LPReported CIK 0001813270
Shares: 1,075,952.00 · Class: 9.98%
- BIOS CAPITAL MANAGEMENT, LPReported CIK 0001813845
Shares: 1,075,952.00 · Class: 9.98%
- CAVU ADVISORS, LLCReported CIK 0001813310
Shares: 1,075,952.00 · Class: 9.98%
- BIOS ADVISORS GP, LLCReported CIK 0001813844
Shares: 1,075,952.00 · Class: 9.98%
- LESLIE W. KREISReported CIK 0001813316
Shares: 1,075,952.00 · Class: 9.98%
- AARON G.L. FLETCHERReported CIK 0001789490
Shares: 1,075,952.00 · Class: 9.98%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-059524
- Form type
- SCHEDULE 13D/A
- Filer
- Bios Equity Partners, LP
- CIK
- CIK 1813314
- Filed
- Jun 13, 2025
- Reporting period
- Jun 12, 2025
- Description
- Schedule 13D beneficial ownership